February 01, 2021
1 min read
Save
FDA grants fast track designation to GLR2007 for glioblastoma
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
The FDA granted fast track designation to GLR2007 for treatment of glioblastoma, according to the agent’s manufacturer.
GLR2007 (Gan & Lee Pharmaceuticals) is a cyclin-dependent kinase 4/6 inhibitor in development for treatment of advanced solid tumors.
Glioblastoma is the most common brain and central nervous system malignancy, accounting for approximately 45% of primary tumors. More than 80% of patients die within 2 years of diagnosis, and nearly 95% die within 5 years.
“The poor prognosis and low survival rates for glioblastomas demonstrate an unmet need for new treatment options,” Julius Huang, PhD, DABT, director of global clinical sciences with Gan & Lee, said in a company-issued press release.
Published by:
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.